Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent.
Park
Ji-Ae
JA
Department of Medical and Biological Engineering, Kyungpook National University, Daegu 702-701, Korea.
Lee
Jae-Jun
JJ
Jung
Jae-Chang
JC
Yu
Dae-Yeul
DY
Oh
Chilhwan
C
Ha
Seunghan
S
Kim
Tae-Jeong
TJ
Chang
Yongmin
Y
D000818:Animals; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002645:Chickens; D003287:Contrast Media / Q000138:chemical synthesis / Q000737:chemistry* / Q000633:toxicity; D011905:Genes, ras; D006571:Heterocyclic Compounds / Q000737:chemistry*; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000737:chemistry*; D009942:Organometallic Compounds / Q000737:chemistry*; D011485:Protein Binding
D003287:Contrast Media; D006571:Heterocyclic Compounds; D039302:Integrin alphaVbeta3; D009842:Oligopeptides; D009942:Organometallic Compounds; C047981:arginyl-glycyl-aspartic acid; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate